All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: A retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand

Bone Marrow Transplantation

Volumn 51, Issue 10, 2016, Pages 1400-1403

  Kruger, P ^a   Cooney, J ^a   Nivison Smith, I ^b   Dodds, A ^c   Bardy, P ^d   Ma, D ^c   Szer, J ^e   Durrant, S ^f  

^a FIONA STANLEY HOSPITAL   (Australia)

^b Australasian Bone Marrow Transplant Recipient Registry   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AUSTRALIA; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LETTER; LEUKEMIA RELAPSE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW ZEALAND; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL ANALYSIS; SURVIVAL TIME; ALLOTRANSPLANTATION; BLAST CELL CRISIS; MORTALITY; PROCEDURES; RETROSPECTIVE STUDY; STANDARDS; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; BLAST CRISIS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MIDDLE AGED; NEW ZEALAND; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84969752628     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2016.143     Document Type: Letter

References (15)

1. Saussele S, Lauseker M, Müller MC, Gratwohl A, Beelen D, Bunjes DW et al. 2567 Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: update on the survival outcome following allogeneic HSCT after imatinib failure; results of the German CML Study IV. 56th ASH Annual Meeting and Exposition; 6-9 December 2014; San Francisco, CA, USA.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
3. Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukaemia in the 21st century. Blood 2015; 125: 3230-3235.
4. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421-1423.
5. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DD, Moore JJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905-912.
6. Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2012; 47: 749-756.
7. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E et al. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukaemia in the imatinib era. Clin Lymphoma Myeloma 2009; 9(Suppl 3): S261-S265.
8. Jabbour E, Cortes J, Santos FPS, Jones D, O'Brien S, Rondon G et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011; 117: 3641-3647.
9. Jiang H, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 2014; 49: 1146-1154.
10. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872-874.
11. Weiden PL, Flournoy N, Thomas ED. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068-1073.
12. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukaemia. Blood 2008; 112: 3500-3507.
13. Egan DN, Beppu L, Radich JP. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation. Biol Blood Marrow Transplant 2015; 21: 184-189.
14. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91: 663-666.
15. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukaemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012; 119: 4083-4090.